Patachi, B. et al. 2025. Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data. Acta Oncologica. 64, (Jan. 2025), 143–146. DOI:https://doi.org/10.2340/1651-226X.2025.42128.